A series of η 4 -acyloxycyclohexadiene-Fe(CO) 3 complexes was prepared and fully characterized by spectroscopic methods including single crystal X-ray diffraction. For this purpose a new synthetic access to differently acylated 1,3-and 1,5-dienol-Fe(CO) 3 complexes was developed. The enzymatically triggered CO release from these compounds was monitored (detection of CO through GC and/or by means of a myoglobin assay) and the anti-inflammatory effect of the compounds was assessed by a cellular assay based on the inhibition of NO-production by inducible NO synthase (iNOS). It was demonstrated that the properties (rate of esterase-triggered CO release, iNOS inhibition, cytotoxicity) of the complexes strongly depend on the substitution pattern of the π-ligand and the nature of the acyloxy substituent.
Introduction
Carbon monoxide (CO) has recently been recognized as an important signalling molecule in mammals. 1 Most of the endogenously produced CO is generated in the course of oxidative heme degradation by the heme oxygenase (HO) enzymes. One of the isoforms of these enzymes (HO-1) is inducible and up-regulated as a response to stress. 2 CO induces several beneficial biological effects, such as cytoprotection, vasodilation, or inhibition of inflammation, 3 and there are clinical studies on different medical applications. 4 One attractive option to deliver CO (avoiding the use of toxic CO gas) is the use of CO-releasing molecules (CORMs). 5 Motterlini and co-workers established this constantly growing field by the identification and evaluation of certain transition metal carbonyl complexes, such as [Mn 2 (CO) 10 ] (CORM-1), fulfilling this function. 6 Later, compounds with improved properties were developed. A prominent example is fac-[RuCl(glycinato)(CO) 3 ] (1, CORM-3), 7 a water soluble complex that releases CO under physiological conditions and is undoubtedly the most studied CORM (Fig. 1) . 8 While a number of different CORMs were shown to exhibit promising activities in various biological investigations, 9 an important unsolved challenge is the delivery of controlled amounts of CO to a target tissue. A general strategy to achieve this aim is the use of stable molecules, which release CO only after activation by means of a trigger. 10 Two possibilities are (1) the pH-dependent CO release from boranocarbonate (2, CORM-A1) 11 or aminoderivatives thereof, 12 or (2) the UV-triggered CO release from transition metal carbonyl complexes. 13 As a novel concept, we recently introduced acyloxybutadieneFe(CO) 3 complexes of type 3 as enzyme-triggered CO-releasing molecules (ET-CORMs). 14 The earlier observation, that enol complexes of type 4 are labile and decompose under oxidative conditions, suggested their suitability as CORMs (Scheme 1). As stable (and "storable") precursors we devised the corresponding esters, i.e. acyloxydiene complexes of type 3, which are sufficiently stable under physiological conditions but are readily converted to the "active" species 4 by means of enzymatic hydrolysis. Thus, once a complex of type 3 enters a cell, cleavage of the ester function by an intracellular esterase triggers the desired CO-release by generating the labile enol complex 4. The oxidative decomposition of this type of intermediate ( presumably via a 16-VE species of type 5) leads to the liberation of the enone ligand and to the release of three molecules of CO (Scheme 1). In our initial study we succeeded in proving the concept, i.e. the enzyme-triggered CO-release from compounds of type 3, by synthesis and evaluation of complexes rac-6, rac-7, rac-8 and rac-9 (Scheme 2, inner circle). These compounds showed very promising effects in a cellular assay based on the inhibition of NO-production by inducible NO-synthase (iNOS). Moreover, a strong dependency of the reactivity (towards enzymatic ester hydrolysis) and the biological activity on the structure of the complexes was observed. These interesting results prompted us to further explore this class of compounds. We here disclose the results of a much more detailed study, which has led to the identification of pronounced structure-activity relationships.
Results and discussion

Synthesis
The various acyloxydiene-Fe(CO) 3 complexes used in the present study are displayed in Fig. 2 . Compounds rac-6, rac-7 and rac-8 were synthesized as described before.
14 Di-acetates rac-9 and rac-16 were prepared using a slightly modified version of the Boháč procedure. 15 Complex rac-10 was synthesized from cyclohexenone (19) by deprotonation with LiHMDS in the presence of TPPA (2.5 equiv.) followed by O-acylation of the resulting dienolate with pivaloyl chloride (PivCl). The resulting dienyl pivalate 20 was treated with Fe 2 (CO) 9 in refluxing diethyl ether to generate the desired complex rac-10 in good yield (Scheme 2).
The three complexes rac-11, rac-12 and rac-13 were synthesized in a similar manner, starting from different cyclohexenones. Compound rac-11 was prepared starting from 4,4-dimethylcyclohexenone (21) 16 by deprotonation with LDA and trapping of the resulting dienolate with Ac 2 O. Complexation of the resulting dienyl acetate 22 then afforded rac-11 (Scheme 3).
Complexes rac-12 and rac-13 were synthesized from 5,5-dimethylcyclohexenone (23), which was obtained from dimedone (27) using the two-step protocol of Wawrzénczyk and Lochyński. 17 Regioselective deprotonation of 23 under either kinetic (LDA, THF) or thermodynamic (LiHMDS, TPPA) 14 control, subsequent O-acetylation and final complexation led to rac-12 and rac-13, respectively, as pure isomers after chromatography (Scheme 4).
The complexes rac-14 and rac-15 were readily obtained from the 1,3-diketones 26 or 27 in a three-step procedure. At first, the β-pivaloxy-substituted enones (vinylogous anhydrides) 28 and 29, respectively, were prepared. Subsequent deprotonation with LDA, O-pivaloylation of the enolate intermediates and complexation then afforded the desired products (Scheme 5). 18 An attempt to apply a related protocol to the synthesis of the dienyl palmitate complexes rac-17 and rac-18 failed, because we could not achieve the synthesis of the dienyl palmitates (as complexation precursors). The problem was solved (according to the strategy of Yeh and Hwu) 19 by first preparing a siloxy-substituted complex (rac-34/35) and subsequently replacing the silyl by an acyl unit (Scheme 6). The siloxydiene 32 was obtained from 19 with LDA and TMSCl. Subsequent complexation afforded rac-34 which, without isolation, was deprotected by chromatography on SiO 2 under inert conditions (N 2 ) to give the dienol complex rac-36. This sensitive compound was immediately converted to the desired ester rac-17 with NaH and the acid chloride. A drawback of this sequence is the low yield (and low reproducibility) resulting from the necessity to isolate the highly labile intermediate rac-36, which is a compound of type 4.
To overcome this disadvantage we deprotected the raw complexation product (rac-34) by addition of TBAF and reacted the in situ-formed dienol complex directly with NaH and the acid chloride. This way, the desired complex rac-17 was obtained with an improved yield and good reproducibility. Using the TIPS-derivative 33, the siloxy-substituted diene complex rac-34 was stable enough to be purified by chromatography and rac-17 was obtained in a greatly improved overall yield (Scheme 6).
The synthesis of the isomeric compound rac-18 was achieved by applying a related methodology (Scheme 7). The TMS-protected diene, i.e. (cyclohexa-1,3-dien-1-yloxy)trimethylsilane, was not synthesized, but the corresponding more stable TIPS derivative 37 (obtained from 19 with LiHMDS/TPPA and TIPSOTf ) allowed us to prepare the siloxydiene complex rac-38 in excellent yield. Deprotection with TBAF and trapping of the resulting di-enolate complex with palmitoyl chloride in the presence of a base (NaH or DIPEA) gave rise to rac-18 in high yield (Scheme 7).
To evaluate also the biological activity of the expected organic by-products of the particularly active ET-CORMs (rac-9 and rac-16), the enones 39 and 40 were required as reference substances. These compounds were prepared from the diketones 26 and 27 20 by reaction with AcCl in the presence of pyridine (Scheme 8).
X-Ray diffraction and analytics
All of the prepared acyloxydiene-Fe(CO) 3 complexes (Fig. 2) proved to be reasonably air-stable and were fully characterized by the common spectroscopic methods. The structures of the complexes rac-10, rac-11, rac-12, rac-14, rac-15, rac-17 and rac-18 were additionally confirmed by X-ray crystal structure analysis (Fig. 3) .
The different positions of the ester substituents, the additional methyl substituents and the different acyl groups did not induce any significant change of the boat-type conformation or the bond lengths within the cyclohexadiene ring. In all cases, the diene moiety of the molecules is virtually planar, with C-C-C-C torsion angles of 0.2-3.6°. The Fe(CO) 3 tripod adopts a conformation with one CO ligand eclipsing the Csp 3 -Csp 3 single bond. The molecular structures are depicted in Fig. 3 . For the X-ray crystallographic data and structural details, see Table 4 and the ESI. †
Detection of the CO-release
Prior to the in vitro evaluation of the CO-releasing properties of the various iron complexes, we had to identify suitable esterases for the enzymatic hydrolysis. In the course of our previous study, pig liver esterase (PLE) and lipase from Candida rugosa (LCR) had proved to be most suitable (out of several commercial esterases initially screened). For this reason we investigated the hydrolysis of the different complexes using these enzymes. The kinetic resolution of the (racemic) compounds was taken as unambiguous proof of enzymatic hydrolysis. For this purpose the enantiomeric excess of the remaining complex was determined by means of HPLC or GC on a chiral stationary phase. In some cases (rac-14, rac-15, rac-17 and rac-18) no sufficient enantiomer separation was achieved. In these cases we used the CO-release, as determined by the myoglobin (Mb) assay or GC (see below), as an indirect method to prove the enzymatic cleavage. 21 Noteworthy, PLE of high purity (130 U mg −1 ) was required for the Mb assay to prevent Mb degradation by protease impurities. Nevertheless, these impurities of the cheaper PLE (15 U mg −1 ) proved to be beneficial for the hydrolysis of certain complexes (monitored by GC detection of the CO release). The results of the various hydrolysis experiments are summarized in Table 1 . 
Conversion was detected as follows: a By measuring the kinetic resolution by GC or HPLC on a chiral stationary phase.
b By detecting the CO-release by means of the Mb-assay.
c By detecting the CO-release through GC. PLE: pig liver esterase; LCR: lipase from Candida rugosa.
The esterase-triggered CO-release from the compounds was detected, but not quantified, using the myoglobin (Mb)-based assay established by Motterlini et al. 6 To obtain more precise information on the (relative) rates and the quantities of released CO, the enzyme-triggered CO-release of complexes rac-6 to rac-18 was additionally monitored by GC. 22 The times for the release of 0.5 mol of CO per mol of ET-CORM (t 0.5 ) 23 from the different complexes under standard conditions (with the specified enzyme) are listed in Table 2 . In agreement with the proposed chemical mechanism (Scheme 1), the enzymetriggered CO release from the acyloxydiene-Fe(CO) 3 complexes was found to be associated with a consumption of oxygen in the reaction system, as indicated by a decrease of the O 2 peak connected to the growth of the CO peak (Fig. 4) .
As a consequence, the calibration of the GC measurements to quantify the amount of CO formed required particular effort (see ESI †). The results shown in Table 2 reveal the following trends.
(1) The CO release from the pivalates and palmitates, respectively, was slower (as compared to the acetates) which corresponds to the expected slower rates of (also enzymatic) hydrolysis. 24 ( 2) The CO release from the complexes with an ester function at the outer position of the diene (rac-8, rac-10 and rac-18) was much faster than the CO release from the complexes with the ester function at the inner position (rac-6, rac-7 and rac-17).
This effect results either from a slower rate of ester hydrolysis (dependent on the enzyme used), a lower stability (faster oxidative decay) of the resulting enol intermediates (related to 4), or a combined effect. (3) The CO release from the diacetate complexes proved to be the fastest. This might be caused by a faster ester hydrolysis or a lower stability of the initially formed enol complex. It also cannot be excluded that hydrolysis of the second ester function triggers an accelerated CO release.
Biological activity
The inducible form of NO-synthase (iNOS) is a dimeric heme protein whose action leads to the formation of NO and L-citrulline from L-arginine in the presence of O 2 and NADPH. 25 The NO released by mammalian cells is employed against invaders such as viruses, bacteria and parasites as well as tumor growth. 26 The influence of CO on the activity of the pro-inflammatory enzyme iNOS can be either on the transcriptional level or on the protein level (Fig. 5) . On the transcriptional level, different mechanisms come into play where the activation of the transcription factor nuclear factor-κB (NF-κB) 27 can be inhibited and thus the expression of iNOS. All three decomposition products of ET-CORMs, Fe 3+ ions 28 and CO 29 as well as the corresponding enones such as cyclohexenone, 30 have been reported to attenuate iNOS protein levels. Enones are of importance since they interfere with the thiol-regulated activation of NF-κB through Michael additions. 31 On the protein level, the enzyme activity of iNOS can be blocked with CO by either inhibiting the formation of the active dimeric form 29 of iNOS or binding of CO to the iron center of the heme prosthetic group. 32 This leads to the deterioration of its catalytic activity to produce NO (Fig. 5) . Therefore, the ET-CORMs can act in different ways when inhibiting the production of NO by iNOS. Both their ability to release CO and their decomposition products (i.e. the corresponding enones and Fe 3+ ) or a combination thereof may be responsible for the observed activity of the ET-CORMs. That is also true for potential toxic effects, which may additionally be attributed to the complexes themselves.
The biological activity of the ET-CORMs was assessed (using the murine macrophage cell line RAW264.7) by determining their influence on (1) the lipopolysaccharide (LPS)-induced production of NO by iNOS and (2) the cell viability (Table 3 ). The latter was determined by means of the MTT assay and crystal violet staining, while the inhibition of NO-production was analyzed by the Griess assay.
An overview of the results (including our previous results 14 ) is given in Table 3 . For a more detailed presentation of the data, see Fig. 6 and the ESI. † a The determination of the absolute amount of CO was complicated by the consumption of oxygen, which varied for the individual compounds (but always stayed in the same range). The average consumption of oxygen was considered in the calibration, but deviations in the range of ±0.2 equiv. cannot be excluded. b In cases where the CO release still proceeded when the detection was stopped, "n.f." (not finished) is added as a suffix. The data given in Table 3 immediately reveal compounds rac-8, rac-9, rac-13, rac-15, and rac-16 as being most promising. Interestingly, diacetates rac-9 and rac-16, which differ structurally only by the two additional methyl groups in the 5-position of the cyclohexadiene ring (in rac-16), show a similar reduction of NO-formation at 5 μM (about 34%). However, complex rac-16 is already active at 1.0 μM (7.7%) but due to its toxicity no measurements were performed at concentrations above 5 μM. The less toxic compound rac-9 reduced the NOproduction at concentrations ≥5.0 μM, and exhibited a remarkable maximum effect of 66% NO-inhibition at 20 μM (the highest non-toxic concentration). The "outer" monoacetate rac-8 also displayed good inhibition of NO production (49% at 10 μM) but proved again to be more toxic than its dimethylated analog rac-13, which showed a particularly clear concentration dependency of its iNOS-inhibiting effect (Fig. 6C) . The dipivalate rac-15 was less toxic than the corresponding diacetate (rac-16) but also significantly less active. However, because of the lower toxicity a higher maximum inhibition could be reached (42% at 25 μM). Nevertheless, the most significant inhibition of NO-production was reached with compound rac-13 (79% at 100 μM) as a consequence of its exceptionally low toxicity.
To probe whether the observed activity is merely an effect of CO and cannot be attributed to the enone decomposition products, we also tested the enones 19, 23, 39, and 40 ( Fig. 7) for their toxicity and influence on NO-production with LPS-stimulated mouse macrophages.
Enone 39 is not toxic and no NO-inhibition activity was found in the concentration range (1.0-5.0 μM) used for the assessment of rac-16 (Fig. 6E) . Therefore, the NO-inhibition caused by rac-16 must be attributed to the CO release. A similar outcome was obtained for rac-9 and its decomposition product, i.e. the enone 40. However, a completely different situation was observed for the mono-acetoxy-substituted complex rac-13 bearing two geminal methyl groups. In this case, both rac-13 and its parent enone 23 possess no toxicity but show a very . 25 Inducers of transcription: LPS, lipopolysaccharide; IFN-γ, interferon-γ; ROS, reactive oxygen species/oxidative stress; IL-1β, interleukin-1β; TNF-α, tumor necrosis factor-α. Inhibitors of transcription (= inhibitors of nuclear factor-κB (NF-κB) activation): glucocorticosteroids, antioxidants, transforming growth factor-β1 (TGF-β1) or enones. IκBα, NF-κB inhibitor α. Significant minimum and maximum NO-inhibition values are given at concentrations that had no toxic effects. *An unusual color was observed with rac-7 and rac-15 in the MTT assay prohibiting a correct assessment of the cell viability, therefore a cell count was done via the crystal violet assay. a Values taken from ref. 14.
b No significant inhibition was observed at this concentration.
c No inhibition could be assigned due to toxicity at this concentration.
strong NO-inhibition of 19-79% at concentrations of 5-100 μM for rac-13 (Fig. 6C ) and of 18-83% at 5-100 μM for enone 23 (see also the ESI; Fig. S28B †) which are essentially the same. This indicates that the enone strongly contributes to the overall activity of the complex in this case and might even exceed the activity of the released CO.
On cleavage of the "outer" acetate complex rac-8, i.e. the non-dimethylated derivative of rac-13, enone 19 (cyclohexenone) is liberated, which is a known inducer of phase 2 enzymes through thiol-regulated Michael addition chemistry.
30 Both rac-8 and 19 show equal activity in the Griess assay (10% for rac-8 14 and 12% NO-inhibition for 19 at 1.0 μM). However, rac-8 exhibits significant toxicity down to 10 μM whereas cyclohexenone displays no toxicity at this concentration (see ESI, Fig. S28A †) . This observation points to a distinct CO effect causing the toxicity of rac-8 or a toxic effect of complex rac-8 itself. Furthermore, the comparison of dimethyl-substituted mono-acetoxydiene complexes rac-11, rac-12 and rac-13 reveals that in this case the "inner" complexes (rac-11 and rac-12) are inferior because of their much higher toxicity compared to rac-13. The inner mono-pivaloate complex rac-7, 14 the dimethyl-dipivaloate rac-14, as well as both palmitates (rac-17 and rac-18) proved to be completely unable to inhibit the production of NO, which indicates poor or no decomposition of these complexes by the intracellular esterases of the particular cell line.
From our biological data we can deduce the structure-activity relationships summarized in Fig. 8 . Most importantly, an "outer" dienyl-acetate core-structure (corresponding to rac-8) proved to be essential for high (desired) biological activity. Introduction of more bulky ester units resulted in reduced NO-inhibition activity together with lower toxicity. The diesters were generally more toxic and exhibited greater NO-inhibition power as compared to the monoesters. Geminal dimethylation at the cyclohexadiene ring reduced the toxicity without inducing a too strong loss of activity. Therefore, rac-9 and rac-13 are the "best" compounds, with rac-9 being more potent but also more toxic than rac-13. Overall, rac-13 is considered superior to rac-9 due to its substantially lower cytotoxicity.
Since the (enzyme-triggered) decomposition of the ET-CORMs not only leads to a release of CO (and the enone ligand) but also to the liberation of iron ions, the influence of Fe 2+ and Fe 3+ upon the viability and NO-production of RAW264.7 cells was also assessed. Both FeCl 2 
Conclusions
We have investigated a series of thirteen acyloxycyclohexadiene-Fe(CO) 3 complexes as a powerful new class of CO-releasing molecules (ET-CORMs), which are activated by enzymatic cleavage of the ester functionality. In the course of the study, new efficient synthetic protocols were developed based on the use of (stable) triisopropylsilyloxydiene complexes as intermediates which can be converted into the corresponding esters in a one-step procedure. The complexes prepared (in racemic form) were fully characterized and their ability to release CO upon enzymatic cleavage was investigated in detail. The experimental results (including the consumption of oxygen) are in accordance with the proposed CO release mechanism. In biological investigations the cytotoxicity and the inhibition of NO-production (as an expected consequence of an interaction of CO with iNOS) was assessed using murine macrophage (RAW264.7) cells. In the context of the study, clear structure-activity relationships could be identified. Two ET-CORMs (rac-9 and rac-13) exhibited particularly promising properties, which to the best of our knowledge make them the most potent CORMs ever studied in this type of assay. We also assessed the biological activity of the expected by-products of the CO release to test whether the biological activity is solely an effect of CO or a combined effect of all the "decomposition" products. These experiments revealed that the enone by-products strongly contribute to the NO-inhibition in the case of the monoesters, but not in the case of the diesters. The iron ions did not induce significant inhibition of the NO-production in the concentrations tested. The results presented here suggest that the iron-based ET-CORMs open up promising options for the future development of small molecules, allowing a controlled and possibly even tissue-selective CO delivery. A next goal is to fine-tune the pharmacological and biological properties, for instance by preparing compounds with higher water solubility.
Experimental
A detailed description of the synthesis of all compounds, including the not commercially available starting materials, of all performed CO-detection experiments (including the measured data) and of the used analytic methods can be found in the ESI. † NMR spectra were recorded on Bruker instruments (Avance DPX 300, Avance DRX 500 or Avance II 600). UV/Vis spectra were recorded on a Beckmann Coulter DU 800 (cell length 1 cm). IR spectra were recorded on a Perkin-Elmer Paragon 1000 FT-IR spectrometer in the ATR mode at room temperature. Mass spectra were recorded at the Central Analytics Department -Mass Spectroscopy, University of Regensburg and the Analytical Service Unit, University of Cologne on Finnigan instruments (a MAT Inocs 50 galaxy system (for EI LR-MS) and a MAT 900 (for HR-MS)). An Agilent Technologies Model GC 6890N gas chromatograph coupled with an HP 5973N series mass selective detector and an HP 7683 GC autosampler was employed for all GC-MS analyses.
Enantiomeric analyses through GC were performed on an Agilent (HP 6890) instrument with FID detection using either a BGB-176SE column (A) or a 6TBDMS-2,3-Me-β-CD column (B). Enantiomeric analyses through high performance liquid chromatography (HPLC) were conducted with HPLC units from Merck-Hitachi and Knauer (UV-detection at 220 nm and 254 nm) using one of the following columns: Diacel Chiracel OD-H (1), Diacel Chiracel OJ (2), Diacel Chiralpak AD-H (3), Macherey Nagel Nucleocell (4) and n-Hex-i-PrOH (99 : 1, 98 : 2 or 95 : 5) as a solvent. Gas chromatograms for the CO-detection were recorded using a Varian CP-3800 gas chromatograph with helium as the carrier gas and a 3 m × 2 mm packed molecular sieve 13× 80-100 column. The gases were detected using a thermal conductivity detector (Varian) operated at 150°C. CHN analyses were conducted on an Elementar Vario EL machine.
All reactions were carried out in flame-dried glassware under an argon atmosphere. Chemicals were purchased from Merck, Sigma-Aldrich, Fluka, Acros, Lancaster or Strem and used without further purification. Solvents were dried following standard procedures (ESI †). The release of CO via the Mb-assay was performed as previously described. 14 
Crystallographic details
Measurements were made on a Nonius Kappa-CCD diffractometer with Mo-Kα radiation (λ = 0.71073), and Denzo was used for data reduction. The structures were solved by direct methods (Shelxs97). 33 Shelxl97 was used for full-matrix least-squares refinement on F 2 . All non-hydrogen atoms were refined anisotropically. All hydrogen atoms were placed in geometrically idealized positions and refined by using a riding model. Ortep plots were generated with Platon. 34 The absorption correction (X-RED) was performed after optimizing the crystal shape using X-SHAPE. Crystal structure determination details are summarized in Table 4 .
Detection of the CO release by GC
All reactions were performed in headspace vials -10 mL (BGBanalytics, Cat. No. 200410-F). Prior to the detection of the CO release, a calibration was done using the same solvent mixture (1 mL of phosphate buffer (0.1 M, pH = 7.4) and 0.2 mL of DMSO) that was used for the CO release experiments. For the CO calibration, the consumption of oxygen had to be included. For this purpose the reaction vial was filled with the solvent mixture and completely degassed with nitrogen. Afterwards, 21% of the gas volume was replaced by oxygen to generate the composition of air (2.250 mL). To generate gas mixtures that are formed when a particular amount of O 2 is consumed in the course of the CO release, the volume of added oxygen was decreased by the amount that is theoretically needed for the release of the added CO. The resulting gas mixture was warmed to 37°C for 10 min prior to the injection and analysis of 50 μL samples by GC. The determined areas from the GC signals were plotted against the amount of O 2 or CO (calculated with the ideal gas law) and fitted (linear for 1.0 equiv., 1.5 equiv. and 2.0 equiv. and exponential for 4.0 equiv. and no O 2 consumption). Thus, for the CO and O 2 calibration, different equivalents of released CO per consumed O 2 were used (1.0 equiv., 1.5 equiv., 2.0 equiv., 4.0 equiv. and no O 2 consumption) and the calibration data were compared to the experimental data of the CO release curves. The data for 1.0 equiv., 1.5 equiv. and 2.0 equiv. matched best and were quite similar. Therefore, an average of the three slopes was taken for the calculation of the released CO.
To monitor the enzyme-triggered CO release, the particular complex (36 μmol) was dissolved in DMSO (0.2 mL) and phosphate buffer (1 mL; 0.1 M, pH = 7.4) was added. The particular enzyme (15 mg of PLE or 20 mg of LCR) was added and the vial was closed with a rubber vial cap. The reaction mixture was stirred at 37°C. From time to time samples (50 μL) were taken and the CO release was quantified. The half-life times were determined directly from an exponential fit of the CO-release (first or second order).
Cells and cell culture
The murine macrophage cell line RAW264.7 35 was kept under standard cell culture conditions using RPMI with 10% heat-inactivated fetal calf serum (FCS) and 2 mM glutamine (Invitrogen, Karlsruhe, Germany).
Determination of cell viability by MTT assay
Cell viability was evaluated by MTT assay as described before. 14 In brief, cells were seeded in 96-well plates at a density of 5 × 10 3 per well, cultured for 24 h, and then incubated for another 24 h with medium supplemented with compounds and 10 ng mL −1 of LPS (Sigma). Controls received only culture medium with LPS or with solvent and LPS. Afterwards, supernatants were removed, 100 μL of MTT solution was added to each well, and cells were incubated for another 3 h at 37°C. Subsequently, 100 μL of SDS-solution (10%) was added, and formazan was allowed to dissolve overnight. Absorbance was determined at 560 nm with a multi-well plate photometer (TiterTek).
Determination of cell proliferation by crystal violet staining
The crystal violet staining was used if it was not possible to get a reliable result in the MTT test because of interference of the substances with MTT, and was performed as described previously. 14 In brief, cells were seeded in 96-well plates at a density of 5 × 10 3 per well, cultured for 24 h, and then treated according to the MTT assay. Afterwards, supernatants were removed and cells were stained with 30 μL crystal violet solution per well for 10 min. Crystal violet was removed, cells were washed with 200 μL aqua dest. and allowed to air-dry overnight. Crystal violet was then solubilized by addition of 100 μL EtOH- Table 4 Crystal data, data collection and refinement parameters for rac-10, rac-11, rac-12, rac-14, rac-15, rac-17 100 (2) 100 (2) 100 (2) 150 (2) 100 (2) 100 (2) Na-citrate solution per well and absorbance was determined at 560 nm.
Measurement of nitrite production by Griess assay
Generation of NO was determined by the Griess reaction which is based on the detection of accumulating nitrite in the cell culture medium. 36 The assay was performed as described previously.
14 Briefly, cells were seeded in 96-well plates at a density of 8 × 10 4 per well, cultured for 24 h and subsequently incubated for another 24 h with medium supplemented with compounds and 10 ng mL −1 of LPS. Afterwards a volume of 100 μL culture supernatant was mixed with 100 μL of Griess reagent. After 15 min incubation at room temperature, absorbance was determined at 560 nm. The nitrite content was determined by using sodium nitrite as the standard.
Data evaluation/statistical analysis
Experiments were carried out with at least four parallels and repeated independently at least three times. Results are expressed as mean ± SD and are depicted as a percentage of untreated controls. A sigmoidal logistic function was used to fit dose-response curves and to determine IC 50 and IC 20 values, using a Microsoft Excel calculation sheet (Ed50plus, v1.0, April 2000, Mario H. Vargas, Instituto Nacional de Enfermedades, Mexico). Statistical analysis was performed using the software Prism (GraphPad Software). Quantitative data were tested with a twotailed paired Student's t-test referring to the untreated control. Levels of significance: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
Syntheses
Synthesis of the γ-pivalate substituted enones 28 and 29. A solution of cyclohexa-1,3-dione (1.0 equiv.) and pyridine (2.0 equiv.) in DCM was cooled to 0°C. Pivaloyl chloride (1.5 equiv.) was added dropwise and the reaction mixture was stirred (1 h). Afterwards water was added, the phases were separated and the aqueous phase was extracted with DCM. The combined organic phases were dried over anhydrous MgSO 4 , the solvent was evaporated and the raw product was purified by column chromatography. 40 (s, 2H, H4), 2.27 (s, 2H, H6), 1.28 (s, 9H, H11), 1.12 (s,   6H, H7, H8) . 13 
General procedure 1 for dienyl-ester and silyldienol ether formation
To a solution of diisopropylamine (ca. 1.5 equiv.) in THF was added n-butyllithium (ca. 1.3 equiv.) at −78°C. After stirring the mixture for 10 min, a solution of the particular enone (1 equiv.) in THF was added dropwise (ca. 1 h). Stirring was continued for 1 h at −78°C. Afterwards the particular electrophile (2.5 equiv., 1.2 equiv. for TIPSOTf ) in THF was added dropwise (1 h). After 30 min at −78°C the reaction mixture was allowed to warm to 25°C before it was quenched by addition of saturated aqueous NH 4 Cl. After 10 min the mixture was extracted with MtBE and the organic layer was washed with water and brine and dried over anhydrous MgSO 4 . Finally, the solvent was evaporated and the crude product was purified by column chromatography. 
General procedure 2 for dienyl-ester and silyldienol ether formation
To a solution of hexamethyldisilazane (1.5 equiv.) in THF was added n-butyllithium (1.3 equiv.) at −78°C. After 10 min TPPA (2.5 equiv.) was added and stirring was continued for 20 min at −78°C. Then the particular enone (1.0 equiv.) in THF was added dropwise (1 h). Afterwards the particular electrophile (2.5 equiv., 1.2 equiv. for TIPSOTf ) in THF was added dropwise (1 h). The mixture was stirred for an additional 30 min at −78°C and then allowed to warm to 25°C before it was quenched with saturated aqueous NH 4 Cl. After extraction with MtBE, the organic solution was washed with water and brine and dried over anhydrous MgSO 4 . Finally, the solvent was evaporated and the crude product was purified by column chromatography.
Cyclohexa-1,3-dienyl pivalate (20) . Yield: 900 mg (5.0 mmol, 62%). FT-IR (ATR): ν [cm 
General preparation of diene-Fe(CO) 3 complexes
A Schlenk tube was charged with the diene (1 equiv.) and Fe 2 (CO) 9 (2-3 equiv.) and set under argon by three evacuation/ argon flush cycles. Then, degassed diethyl ether was added and the reaction mixture was heated to reflux for 20 h under argon. Finally, the solvent was evaporated and the crude mixture was purified by column chromatography to yield the desired complex.
(RS)-Tricarbonyl-η 4 -(1-hexadecanoyloxy-1,5-cyclohexadiene)-iron(0) (rac-17). Without column chromatography, the solvent was evaporated, the residue was dissolved in DMF and the solution was added to NaH (3.7 equiv.). The reaction mixture was cooled (0°C) and TBAF (1.8 equiv.) was added dropwise. After 45 min palmitoyl chloride (2.0 equiv.) was added and the reaction was stirred at 20°C (3 h, TLC 78 (m, 1H, H4), 2.28-2.10 (m, 1H, H6) 
